CJ Park works on a variety of national, state, and local research and evaluation projects to determine how education policies and programs can improve the academic and life outcomes of...
Article November 1, 2014
USP8 Regulates Mitophagy by Removing K6-Linked Ubiquitin Conjugates from Parkin
Mutations in the Park2 gene, encoding the E3 ubiquitin-ligase parkin, are responsible for a familial form of Parkinson’s disease (PD). Parkin-mediated ubiquitination is critical for the efficient elimination of depolarized...
Yunsoo Park, PhD, is a senior education researcher in SRI’s Education Division. She has extensive research and clinical experience in social-emotional learning, impacts of trauma and stress, and psychological and...
Article January 1, 2009
Meeting Report: Consensus Statement – Parkinson’s Disease and the Environment: Collaborativeon Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26-28 June 2007
Press Release January 1, 2009
SRI International’s CMOS Imager Aboard the Parker Solar Probe Mission Named Gold Winner of the Edison Awards
Global nonprofit research center recognized for contributions to NASA’s Solar Probe MENLO PARK, CA APRIL 13, 2020 – SRI International today announces that they have won the Gold Edison Award...
Conference Paper November 1, 2014
The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
Previous studies in Parkinsonian rats and monkeys have shown that β2-selective nicotinic acetylcholine receptor (nAChR) agonists reduce l-Dopa-induced dyskinesias (LIDs), a serious complication of l-Dopa therapy for Parkinson’s disease. Since...
Article September 1, 2010
Gene-Environment Interactions in Parkinson’s Disease and Other Forms of Parkinsonism
Jaehyeon Park is a medicinal chemist, who focuses on structure-activity relationship (SAR) studies—the connections between molecules’ chemical structures and their biological activities—to develop more practical, efficient synthetic routes for anticancer...
Article April 1, 2014
ABT-089 and ABT-894 REducation Divisionce Levodopa-Induced Dyskinesias in a Monkey Model of Parkinson’s Disease
Levodopa-induced dyskinesias (LIDs) are a serious complication of levodopa therapy for Parkinson’s disease for which there is little treatment. Accumulating evidence shows that nicotinic acetylcholine receptor (nAChR) drugs decrease LIDs...
Article June 1, 2015
Evidence for a Role for alpha6 nAChRs in L-Dopa-Induced Dyskinesias Using Parkinsonian alpha6 nAChR Gain-of-Function Mice
L-Dopa-induced dyskinesias are a serious side effect that develops in most Parkinson’s disease patients on dopamine replacement therapy. Few treatment options are available to manage dyskinesias; however, recent studies show...
Conference Paper November 1, 2013
α4β2* and α7 Nicotinic Receptors Play a Role in L-Dopa-Induced Dyskinesias; Studies Using Parkinsonian Knockout Mice
L-dopa-induced dyskinesias are a serious long-term side effect of dopamine replacement therapy for Parkinson’s disease for which there are few treatment options. Our previous studies showed that nicotine decreased L-dopa-induced...
Article August 1, 2013
Alpha4beta2 Nicotinic Receptors Play a Role in the nAChR-Mediated Decline in l-Dopa-Induced Dyskinesias in Parkinsonian Rats
l-dopa-induced dyskinesias are a serious long-term side effect of dopamine replacement therapy for Parkinson’s disease for which there are few treatment options. Our previous studies showed that nicotine decreased l-dopa-induced...